Single Dose Bevacizumab as Treatment for Symptomatic, Corticosteroid-Refractory Pseudoprogression After Chemoradiation Therapy for Newly Diagnosed Glioblastoma: A Case Report

Integrative Cancer Science and Therapeutics
doi 10.15761/icst.1000141
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Open Access Text Pvt, Ltd.

Related search

Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2011English

Boron Neutron Capture Therapy for Newly Diagnosed Glioblastoma

Radiotherapy and Oncology
Nuclear MedicineOncologyRadiologyHematologyImaging
2009English

A Budget Impact Model for the Introduction of Bevacizumab for the Treatment of Newly Diagnosed Glioblastoma Multiforme in the UK

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Addition of Lomustine for Bevacizumab-Refractory Recurrent Glioblastoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2014English

A Phase 1 Trial of ABT-510 Concurrent With Standard Chemoradiation for Patients With Newly Diagnosed Glioblastoma

Archives of Neurology
2010English

Plasma YKL-40 as a Biomarker for Bevacizumab Efficacy in Patients With Newly Diagnosed Glioblastoma in the Phase 3 Randomized AVAglio Trial

Oncotarget
Oncology
2017English

Chemotherapy Plus Concomitant Low-Dose Fractionated Radiotherapy as Second-Line Treatment for Recurrent or Progressive Glioblastoma After Temozolomide-Based Chemoradiation: A Pilot Study.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2011English

Using Temozolomide in Newly Diagnosed Glioblastoma Multiforme – A Single-Centre Experience

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2010English

Ruxolitinib as a Promising Treatment for Corticosteroid-Refractory Graft-Versus -Host Disease

British Journal of Haematology
Hematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy